GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Valuation Rank

Pluri (PLUR) Valuation Rank


View and export this data going back to 1991. Start your Free Trial

What is Pluri Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pluri Valuation Rank Related Terms

Thank you for viewing the detailed overview of Pluri's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pluri Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Valuation Rank
Comparable Companies
IGXT ABIO RNXT VTVT AURX LUMO VINC EQ ELEV OCEA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
PLUR:Israel
Address
MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409
Website
https://www.pluri-biotech.com
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
Executives
Lorne Kenneth Abony director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman officer: Chief Executive Officer 63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership 10 percent owner BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer director 33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun director 9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay officer: Chief Financial Officer ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat director HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram director 24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda officer: Chief Financial Officer MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain director WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi officer: Chief Financial Officer MATAM PARK, BUILDING 05, HAIFA L3 31905